V. von Wyl

Discipline

Psychologie (1) Economies et finances (1)

Type de document

Articles (26) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Treatment (19) Methods (17) Swiss (17) Methods (17) thérapie (16) Therapeutics (16) Patients (15) Patients (15) Human beings (14) cohorte (13) virus (12) Models (12) temps (durée) (11) Time (11) Drug resistance (11) résistance (11) adulte (9) Immunodeficiency (9) adulte (9) art (8) infection (8) Art (8) Art (8) Population (8) Infection (8) Art (8) Use (8) Population (8) art (8) mutation (7)

Documents écrit par V. von Wyl (26) | parle de V. von Wyl (0)

Development of hybrid immunity during a period of high incidence of Omicron infections.
A. Frei et al. (25 déc. 2023)
Factors Associated With COVID-19 Non-Vaccination in Switzerland: A Nationwide Study.
S. Sabatini et al. (2023)
The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing.
D. Chiavi et al. (10 nov. 2022)
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
L. Barin et al.
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
M. Kaufmann et al. (2020)
A step beyond the hygiene hypothesis-immune-mediated classes determined in a population-based study.
V. Ajdacic-Gross et al. (9 avr. 2019)
The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.
N. Steinemann et al. (13 août 2018)
Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.
M. Kaufmann et al. (2018)
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study.
S.M. Drescher et al. (2014)
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
K.J. Metzner et al. (2013)
The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients.
N. Beerenwinkel et al. (2013)
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.
V. von Wyl et al. (2013)
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
A.U. Scherrer et al. (2012)
Inferring epidemic contact structure from phylogenetic trees.
G.E. Leventhal et al. (2012)
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
V. von Wyl et al. (2012)
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.
A.U. Scherrer et al. (2011)
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.
R.D. Kouyos et al. (2011)
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.
V. von Wyl et al. (2011)
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
A.U. Scherrer et al. (2011)
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
V. Von Wyl et al. (2011)
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.
J. Fehr et al. (2011)
Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase
V. von Wyl et al. (2010)
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.
S. Alizon et al. (2010)
HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.
V. von Wyl et al. (2010)
Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland.
V. von Wyl et al. (2009)

next